Satellos Bioscience Inc. (MSCLF) Form 6-K — Aug 14, 2026
Satellos Bioscience entered into an at-the-market equity sales agreement allowing it to issue and sell through an agent up to $50,000,000 of common shares from time to time on Nasdaq at prevailing market prices. The Company is under no obligation to sell any shares, and the agent is under no obligation to purchase shares on a principal basis. The ATM program operates under a Form F-10 registration statement (File No. 333-298223) and an amended and restated Canadian base shelf prospectus, both dated August 11, 2026, each covering up to $300,000,000 of the Company's securities.
Key figures
- Gross Proceeds
- Up to $50,000,000 in common shares issuable under the ATM sales agreement
- Shelf Capacity
- U.S.$300,000,000 under the F-10 registration statement and Canadian base shelf prospectus
- Non Affiliate Market Value
- approximately $180.3 million as of Nasdaq close on August 13, 2026
- Agent Counsel Fee Cap Execution
- $75,000
- Canadian Shelf Prospectus Date
- 2026-08-11 (amending and restating October 29, 2025 prospectus)
- Registration Statement File No
- 333-298223
- Agent Counsel Fee Cap Other Dates
- $15,000
- Registration Statement Effective Date
- 2026-08-11
- Agent Counsel Fee Cap Representation Date
- $25,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.